Copyright Reports & Markets. All rights reserved.

Global Antibody Drug Conjugate Therapeutics Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Mmunomedics Technology
    • 1.2.3 Immunogen Technology
    • 1.2.4 Seattle Genetics Technology
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Antibody Drug Conjugate Therapeutics Market Share by Application: 2020 VS 2026
    • 1.3.2 Lymphoma
    • 1.3.3 Leukemia
    • 1.3.4 Multiple Myeloma
    • 1.3.5 Skin Cancer
    • 1.3.6 Colon Cancer
    • 1.3.7 Glioblastoma
    • 1.3.8 Pancreatic Cancer
    • 1.3.9 Prostate Cancer
    • 1.3.10 Solid Tumor
    • 1.3.11 Breast Cancer
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Antibody Drug Conjugate Therapeutics Market Perspective (2015-2026)
  • 2.2 Global Antibody Drug Conjugate Therapeutics Growth Trends by Regions
    • 2.2.1 Antibody Drug Conjugate Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Antibody Drug Conjugate Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Antibody Drug Conjugate Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Antibody Drug Conjugate Therapeutics Players by Market Size
    • 3.1.1 Global Top Antibody Drug Conjugate Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.2 Global Antibody Drug Conjugate Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Antibody Drug Conjugate Therapeutics Revenue
  • 3.4 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio
    • 3.4.1 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate Therapeutics Revenue in 2019
  • 3.5 Key Players Antibody Drug Conjugate Therapeutics Area Served
  • 3.6 Key Players Antibody Drug Conjugate Therapeutics Product Solution and Service
  • 3.7 Date of Enter into Antibody Drug Conjugate Therapeutics Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody Drug Conjugate Therapeutics Breakdown Data by Type (2015-2026)

  • 4.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Type (2015-2020)
  • 4.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Type (2021-2026)

5 Antibody Drug Conjugate Therapeutics Breakdown Data by Application (2015-2026)

  • 5.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Application (2015-2020)
  • 5.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Antibody Drug Conjugate Therapeutics Market Size (2015-2026)
  • 6.2 North America Antibody Drug Conjugate Therapeutics Market Size by Type (2015-2020)
  • 6.3 North America Antibody Drug Conjugate Therapeutics Market Size by Application (2015-2020)
  • 6.4 North America Antibody Drug Conjugate Therapeutics Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Antibody Drug Conjugate Therapeutics Market Size (2015-2026)
  • 7.2 Europe Antibody Drug Conjugate Therapeutics Market Size by Type (2015-2020)
  • 7.3 Europe Antibody Drug Conjugate Therapeutics Market Size by Application (2015-2020)
  • 7.4 Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Antibody Drug Conjugate Therapeutics Market Size (2015-2026)
  • 8.2 China Antibody Drug Conjugate Therapeutics Market Size by Type (2015-2020)
  • 8.3 China Antibody Drug Conjugate Therapeutics Market Size by Application (2015-2020)
  • 8.4 China Antibody Drug Conjugate Therapeutics Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Antibody Drug Conjugate Therapeutics Market Size (2015-2026)
  • 9.2 Japan Antibody Drug Conjugate Therapeutics Market Size by Type (2015-2020)
  • 9.3 Japan Antibody Drug Conjugate Therapeutics Market Size by Application (2015-2020)
  • 9.4 Japan Antibody Drug Conjugate Therapeutics Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Antibody Drug Conjugate Therapeutics Market Size (2015-2026)
  • 10.2 Southeast Asia Antibody Drug Conjugate Therapeutics Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Antibody Drug Conjugate Therapeutics Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Antibody Drug Conjugate Therapeutics Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Bayer AG
    • 11.1.1 Bayer AG Company Details
    • 11.1.2 Bayer AG Business Overview
    • 11.1.3 Bayer AG Antibody Drug Conjugate Therapeutics Introduction
    • 11.1.4 Bayer AG Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020))
    • 11.1.5 Bayer AG Recent Development
  • 11.2 Pfizer
    • 11.2.1 Pfizer Company Details
    • 11.2.2 Pfizer Business Overview
    • 11.2.3 Pfizer Antibody Drug Conjugate Therapeutics Introduction
    • 11.2.4 Pfizer Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 11.2.5 Pfizer Recent Development
  • 11.3 Hoffman-Le Roche
    • 11.3.1 Hoffman-Le Roche Company Details
    • 11.3.2 Hoffman-Le Roche Business Overview
    • 11.3.3 Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Introduction
    • 11.3.4 Hoffman-Le Roche Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 11.3.5 Hoffman-Le Roche Recent Development
  • 11.4 Seattle Genetics
    • 11.4.1 Seattle Genetics Company Details
    • 11.4.2 Seattle Genetics Business Overview
    • 11.4.3 Seattle Genetics Antibody Drug Conjugate Therapeutics Introduction
    • 11.4.4 Seattle Genetics Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 11.4.5 Seattle Genetics Recent Development
  • 11.5 ImmunoGen
    • 11.5.1 ImmunoGen Company Details
    • 11.5.2 ImmunoGen Business Overview
    • 11.5.3 ImmunoGen Antibody Drug Conjugate Therapeutics Introduction
    • 11.5.4 ImmunoGen Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 11.5.5 ImmunoGen Recent Development
  • 11.6 Genentech
    • 11.6.1 Genentech Company Details
    • 11.6.2 Genentech Business Overview
    • 11.6.3 Genentech Antibody Drug Conjugate Therapeutics Introduction
    • 11.6.4 Genentech Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 11.6.5 Genentech Recent Development
  • 11.7 Synthon Holding
    • 11.7.1 Synthon Holding Company Details
    • 11.7.2 Synthon Holding Business Overview
    • 11.7.3 Synthon Holding Antibody Drug Conjugate Therapeutics Introduction
    • 11.7.4 Synthon Holding Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 11.7.5 Synthon Holding Recent Development
  • 11.8 Sanofi
    • 11.8.1 Sanofi Company Details
    • 11.8.2 Sanofi Business Overview
    • 11.8.3 Sanofi Antibody Drug Conjugate Therapeutics Introduction
    • 11.8.4 Sanofi Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 11.8.5 Sanofi Recent Development
  • 11.9 Genmab
    • 11.9.1 Genmab Company Details
    • 11.9.2 Genmab Business Overview
    • 11.9.3 Genmab Antibody Drug Conjugate Therapeutics Introduction
    • 11.9.4 Genmab Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 11.9.5 Genmab Recent Development
  • 11.10 Amgen
    • 11.10.1 Amgen Company Details
    • 11.10.2 Amgen Business Overview
    • 11.10.3 Amgen Antibody Drug Conjugate Therapeutics Introduction
    • 11.10.4 Amgen Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 11.10.5 Amgen Recent Development
  • 11.11 Novartis
    • 10.11.1 Novartis Company Details
    • 10.11.2 Novartis Business Overview
    • 10.11.3 Novartis Antibody Drug Conjugate Therapeutics Introduction
    • 10.11.4 Novartis Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 10.11.5 Novartis Recent Development
  • 11.12 Eli Lilly
    • 10.12.1 Eli Lilly Company Details
    • 10.12.2 Eli Lilly Business Overview
    • 10.12.3 Eli Lilly Antibody Drug Conjugate Therapeutics Introduction
    • 10.12.4 Eli Lilly Revenue in Antibody Drug Conjugate Therapeutics Business (2015-2020)
    • 10.12.5 Eli Lilly Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Antibody Drug Conjugate Therapeutics Scope and Market Size
    Antibody Drug Conjugate Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antibody Drug Conjugate Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Mmunomedics Technology
    Immunogen Technology
    Seattle Genetics Technology
    Others

    Market segment by Application, split into
    Lymphoma
    Leukemia
    Multiple Myeloma
    Skin Cancer
    Colon Cancer
    Glioblastoma
    Pancreatic Cancer
    Prostate Cancer
    Solid Tumor

    Based on regional and country-level analysis, the Antibody Drug Conjugate Therapeutics market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Antibody Drug Conjugate Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Bayer AG
    Pfizer
    Hoffman-Le Roche
    Seattle Genetics
    ImmunoGen
    Genentech
    Synthon Holding
    Sanofi
    Genmab
    Amgen
    Novartis
    Eli Lilly

    Buy now